急性大血管闭塞性缺血性卒中替罗非班联合机械取栓的匹配对照分析
基于中国两项前瞻性试验的倾向性匹配分析,81例替罗非班联合机械取栓患者与81例单纯取栓患者匹配。联合组成功再通率(91.3% vs 81.5%,P=0.043)和3个月良好预后率(53.1% vs 33.3%,P=0.016)均显著更高,其余结局无显著差异。作者认为替罗非班联合取栓未增加主要安全顾虑,显示出更好疗效的趋势,建议优先开展进一步随机对照试验。
要点
- 替罗非班联合机械取栓组成功再通率91.3%,高于单纯取栓组的81.5%(P=0.043)。
- 联合组3个月良好预后(改良Rankin量表评分0-2)率53.1%,高于单纯取栓组的33.3%(P=0.016)。
- 两组其余结局指标无显著差异,作者建议优先开展进一步随机对照试验。
核心结论
- 该匹配对照研究显示,机械取栓联合替罗非班未引起主要安全性顾虑,与单纯机械取栓相比显示出更好疗效结局的趋势。
- 总体而言,替罗非班与机械取栓联合使用时显示出作为围手术期辅助抗血栓治疗的潜力。
- 作者建议应优先开展机械取栓联合替罗非班的进一步随机对照试验。
研究设计与样本
- 本研究为基于中国人群两项前瞻性试验的倾向性匹配分析。
- ANGEL-ACT试验(急性缺血性卒中血管内治疗关键技术及急救流程改进)纳入111家医院2017年11月至2019年3月的数据。
- EPOCH试验(替罗非班用于急性缺血性卒中血管内治疗)纳入15家医院2019年4月至2020年3月的数据。
- 81例EPOCH联合治疗组患者与81例ANGEL-ACT未使用替罗非班患者进行匹配。
- 调整分析采用混合效应逻辑回归模型以考虑医院内聚类效应。
主要发现
- 与未使用替罗非班组相比,替罗非班组成功再通率显著更高(91.3% vs 81.5%,P=0.043)。
- 替罗非班组3个月良好预后率显著高于未使用替罗非班组(53.1% vs 33.3%,P=0.016)。
- 两组其余结局指标均无显著差异。
- 倾向性评分匹配的所有结局指标与全人群混合效应逻辑回归模型结果一致。
关键数值与推荐
- 主要疗效结局为3个月良好预后,定义为改良Rankin量表评分0-2。
- 次要疗效结局包括3个月改良Rankin量表评分分布、不良预后(改良Rankin量表评分5-6)及成功再通。
- 安全性结局包括任何颅内出血、症状性颅内出血及3个月死亡率。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients undergoing mechanical thrombectomy (MT), adjunctive antithrombotic might improve angiographic reperfusion, reduce the risk of distal emboli and reocclusion but possibly expose patients to a higher intracranial hemorrhage risk. This study evaluated the safety and efficacy of combined MT plus eptifibatide for acute ischemic stroke. METHODS: This was a propensity-matched analysis of data from 2 prospective trials in Chinese populations: the ANGEL-ACT trial (Endovascular Treatment Key Technique and Emergency Workflow Improvement of Acute Ischemic Stroke) in 111 hospitals between November 2017 and March 2019, and the EPOCH trial (Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke) in 15 hospitals between April 2019 and March 2020. The primary efficacy outcome was good outcome (modified Rankin Scale score 0-2) at 3 months. Secondary efficacy outcomes included the distribution of 3-month modified Rankin Scale scores and poor outcome (modified Rankin Scale score 5-6) and successful recanalization. The safety outcomes included any intracranial hemorrhage, symptomatic intracranial hemorrhage, and 3-month mortality. Mixed-effects logistic regression models were used to account for within-hospital clustering in adjusted analyses. RESULTS: Eighty-one combination arm EPOCH subjects were matched with 81 ANGEL-ACT noneptifibatide patients. Compared with the no eptifibatide group, the eptifibatide group had significantly higher rates of successful recanalization (91.3% versus 81.5%; P=0.043) and 3-month good outcomes (53.1% versus 33.3%; P=0.016). No significant difference was found in the remaining outcome measures between the 2 groups. All outcome measures of propensity score matching were consistent with mixed-effects logistic regression models in the total population. CONCLUSIONS: This matched-control study demonstrated that MT combined with eptifibatide did not raise major safety concerns and showed a trend of better efficacy outcomes compared with MT alone. Overall, eptifibatide shows potential as a periprocedural adjunctive antithrombotic therapy when combined with MT. Further randomized controlled trials of MT plus eptifibatide should be prioritized. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03844594 (EPOCH), NCT03370939 (ANGEL-ACT).
引用
- Ma G, Sun X, Cheng H, et al. Combined Approach to Eptifibatide and Thrombectomy in Acute Ischemic Stroke Because of Large Vessel Occlusion: A Matched-Control Analysis. Stroke. 2022. PMID: 35105182. doi:10.1161/STROKEAHA.121.036754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。